Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Sanofi said this morning ... this year from an ever-lengthening list of indications associated with type 2 inflammation. The three pipelines-in-a-product are anti-OX40 antibody amlitelimab ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

PARIS, Oct 20 (Reuters) - Sanofi (SASY.PA), opens new tab on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton ...